Physician profile
Nicholas Kassebaum
NPI 1518160167
$22,808.56
in general payments reported to CMS, 2019-2025
5 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,000 · 2022: $1,950 · 2024: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $14K · Consulting Fee: $4,000 · Food and Beverage: $577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $14,281.26 |
| Consulting Fee | $4,000.00 |
| Food and Beverage | $577.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $14,523.31 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $4,335.25 | 2024 | |
| Merck Sharp & Dohme LLC | $2,000.00 | 2021 | |
| Fujifilm Sonosite, INC. | $1,200.00 | 2022 | |
| Verathon INC. | $750.00 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Kassebaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.